As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.

Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team, has died at 65. | Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team,

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but expensive weight-loss drugs.

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce prescription drug costs.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Turquoise Health is a healthcare pricing platform that has raised over $55 million Vator · Joe Wisniewski, AVP of Channel Sales at Turquoise Health, on the VatorNews podcast In 2025, we may see radical top-down changes to our healthcare system as new heads of the NIH - National Institutes of Health,

Trump’s pick to lead HHS is facing 175 questions from Elizabeth Warren, skepticism from Mike Pence and delays related to his disclosure forms.

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.